Terms: = Germ cell tumor AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Clinical Outcome
1077 results:
1. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.
Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Carus A; Rosenvilde JJ; Berney D; Daugaard G
Eur J Cancer; 2024 May; 202():114025. PubMed ID: 38531266
[TBL] [Abstract] [Full Text] [Related]
3. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
4. [Neurosurgical treatment of tumors of the pineal region - literature review and overview of cases at OMIII].
Mezei T; Báskay J; Pollner P; Kovács V; Markia B; Nagy G; Bajcsay A; Sipos L
Magy Onkol; 2024 Mar; 68(1):27-35. PubMed ID: 38484373
[TBL] [Abstract] [Full Text] [Related]
5. Soft-tissue reconstruction with pedicled vertical rectus abdominis myocutaneous flap after total or high sacrectomy for giant sacral tumor.
Huang W; Hu X; Cai W; Cheng M; Fang M; Sun Z; Hu T; Yan W
J Plast Reconstr Aesthet Surg; 2024 Apr; 91():173-180. PubMed ID: 38417394
[TBL] [Abstract] [Full Text] [Related]
6. GammaTile
Yekula A; Gessler DJ; Ferreira C; Shah R; Reynolds M; Dusenbery K; Chen CC
J Neurooncol; 2024 Feb; 166(3):441-450. PubMed ID: 38281303
[TBL] [Abstract] [Full Text] [Related]
7. The Application of Sodium Fluorescein in Resection of Medulloblastoma Under YELLOW 560 Filter: Feasibility and Preliminary Results of a Monocentric Cohort and Systematic Review.
Falco J; Broggi M; Rubiu E; Schiariti M; Restelli F; Mazzapicchi E; La Corte E; Ferroli P; Acerbi F
World Neurosurg; 2024 Mar; 183():e386-e394. PubMed ID: 38154682
[TBL] [Abstract] [Full Text] [Related]
8. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
10. PATIENT-RELATED FACTORS AND clinical MANAGEMENT outcomeS OF RETINOBLASTOMA IN CALABAR, NIGERIA.
Nkanga ED; Nlemadim AC; Arazi M; Nkanga DG; Duke RE; Fabian ID; Nkanga ED; Odey FA; Meremikwu MM
West Afr J Med; 2023 Dec; 40(12 Suppl 1):S36-S37. PubMed ID: 38070170
[TBL] [Abstract] [Full Text] [Related]
11. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
12. CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis.
Romagnoli G; D'Alessandris QG; Capone I; Tavilla A; Canini I; Lapenta C; Buccarelli M; Giordano M; Tirelli V; Sanchez M; Fragale A; Giannetti S; Di Bonaventura R; Lauretti L; Biffoni M; Ricci-Vitiani L; Pallini R; Gabriele L
Immunology; 2024 Feb; 171(2):198-211. PubMed ID: 37884280
[TBL] [Abstract] [Full Text] [Related]
13. Independent prognostic biomarker FERMT3 associated with immune infiltration and immunotherapy response in glioma.
Zhuo S; Tang C; Yang L; Chen Z; Chen T; Wang K; Yang K
Ann Med; 2023; 55(2):2264325. PubMed ID: 37795794
[TBL] [Abstract] [Full Text] [Related]
14. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
[TBL] [Abstract] [Full Text] [Related]
15. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
16. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic Factors for Relapse in Patients With clinical Stage I Testicular Seminoma: A Nationwide, Population-Based Cohort Study.
Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Rosenvilde JJ; Berney D; Daugaard G
J Clin Oncol; 2024 Jan; 42(1):81-89. PubMed ID: 37683134
[TBL] [Abstract] [Full Text] [Related]
18. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
19. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
20. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed cell Death in Lower Grade Glioma.
Ma W; Mei P
World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
[TBL] [Abstract] [Full Text] [Related]
[Next]
